The research group at the ISM-MCC Frontier Materials Design Laboratory (a joint research division of Mitsubishi Chemical Corporation (MCC) and the Institute of Statistical Mathematics (ISM)) has discovered a phenomenon known as the "scaling law^*a of Sim2Real transfer learning^*b" in the integrated analysis of large-scale computational materials property databases and experimental data, in collaboration with research groups from the National Institute for Materials Science (NIMS).

Phosphodiesterase 3 (PDE3) inhibitors are clinically approved drugs used for treating thrombosis, heart diseases, and asthma. Now, however, scientists have found that PDE3 inhibitors can also stimulate key signaling pathways that trigger Ca2+ influx into bone cells, promoting extracellular matrix production and bone growth. This new therapeutic potential of PDE3 inhibitors was demonstrated using both in vivo and ex vivo approaches, suggesting that existing PDE3 inhibitors could be repositioned as therapies for skeletal disorders. 

Researchers from The University of Osaka found that EGR1-expressing CD14+ monocytes and CD8+ T cells with a type II interferon signature are associated with scleroderma renal crisis and interstitial lung disease, respectively, in patients with systemic sclerosis. Understanding the specific immune cell abnormalities underlying different clinical manifestations of the disease could help predict and prevent serious complications.

Innovation Center of NanoMedicine has published a research result on the website of Journal of Controlled Release on June 5, 2025. The paper titled "Structural stability and RNase resistance of mRNA Polyplex micelles for systemic delivery" describes a method for more stable delivery of mRNA drugs, which are prone to losing their activity to degrading enzymes when mounted in micelles, to target tissues.

Osaka Metropolitan University researchers have successfully increased the production of D-lactic acid from methanol by exposing Komagataella phaffii yeast to ultraviolet irradiation.

A research team at The University of Tokyo has discovered that inhalational anesthetics activate a protein called type 1 ryanodine receptor (RyR1), which contributes to the induction of general anesthesia.

This finding shed light on a long-standing mystery: the mechanism of action of inhalational anesthetics, which has remained only partially understood for nearly 180 years. A precise understanding of how anesthetics work could pave the way for the development of more effective anesthetic agents and improved methods of administration.